Seres Therapeutics (MCRB) Q2 2026 earnings summary

Executive summary

• Focused on developing live biotherapeutic products for oncology and inflammatory diseases, with a pipeline including SER-155, SER-603, SER-428, and SER-147.

• Successfully developed and sold VOWST, the first FDA-approved oral microbiome therapeutic, to Nestlé Health Science in September 2024.

• Achieved net income of $4.6 million in Q2 2026, reversing a net loss of $19.9 million year-over-year, primarily due to a $25 million gain from the VOWST business sale milestone payment from Nestlé.

• SER-155 showed promising results in Phase 1b and investigator-sponsored trials, with 80% of irEC trial participants achieving immunosuppressive-free clinical response at day 15.

• Company implemented significant cost reductions, including a 30% workforce reduction, early lease terminations, and restructuring to lower facility costs.

Financial highlights

• Net loss from operations was $42.2 million for the six months ended June 30, 2026, compared to a net income of $12.8 million in the prior year period, primarily due to the absence of large one-time gains from the VOWST sale.

• Net income of $4.6 million in Q2 2026, compared to a net loss of $19.9 million in Q2 2025.

• Total revenue was $1.1 million for the six months ended June 30, 2026, derived from grant reimbursements (CARB-X).

• Operating expenses decreased to $43.3 million from $52.1 million year-over-year, reflecting lower R&D and G&A costs after cost containment actions.

• Cash and cash equivalents totaled $15.6 million as of June 30, 2026, with an accumulated deficit of $987.7 million.

Outlook and guidance

• Cash runway expected to fund operations through Q1 2027, excluding potential future partnerships or capital sources.

• Additional funding will be required following Q1 2027 to support ongoing operations and development programs.

• Management is actively seeking business development transactions, partnerships, or equity financing to extend cash runway.

• Substantial doubt exists about the ability to continue as a going concern for at least 12 months from the financial statement issuance date.

• Evaluating clinical development strategy for SER-155 in irEC and seeking partners and funding for further advancement.